Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cyproterone acetate
Drug ID BADD_D00555
Description An anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females.
Indications and Usage For the palliative treatment of patients with advanced prostatic carcinoma.
Marketing Status approved; investigational
ATC Code Not Available
DrugBank ID DB04839
KEGG ID D01368
MeSH ID D017373
PubChem ID 9880
TTD Drug ID Not Available
NDC Product Code 53104-7635; 46439-8720; 59010-000
UNII 4KM2BN5JHF
Synonyms Cyproterone Acetate | Cyproterone Acetate, (17 alpha)-Isomer | Cyproterone Acetate, (1 alpha,2 alpha,9 beta,10 alpha)-Isomer | Androcur | Cyproterone Acetate, (1 alpha,2 alpha)-Isomer
Chemical Information
Molecular Formula C24H29ClO4
CAS Registry Number 427-51-0
SMILES CC(=O)C1(CCC2C1(CCC3C2C=C(C4=CC(=O)C5CC5C34C)Cl)C)OC(=O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hepatic failure09.01.03.002--
Hepatic necrosis09.01.07.002--
Hepatic neoplasm16.07.03.001; 09.04.03.001--Not Available
Hepatitis09.01.07.004--Not Available
Hepatomegaly09.01.05.001--Not Available
Hernia08.01.04.001--Not Available
Hirsutism23.02.04.001; 05.05.01.005--
Hypercalcaemia05.04.01.002; 14.04.01.003--
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypernatraemia14.05.04.001--
Hypersensitivity10.01.03.003--
Hyperventilation19.01.02.004; 22.02.01.006--Not Available
Hypochromic anaemia01.03.02.004--Not Available
Hypotension24.06.03.002--
Immune system disorder10.02.01.001--Not Available
Infertility21.03.02.001--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Jaundice cholestatic09.01.01.005--Not Available
Leukocytosis01.02.01.002--
Leukopenia01.02.02.001--Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Libido increased21.03.02.007; 19.08.03.002--
Liver function test abnormal13.03.04.030--Not Available
Loss of consciousness17.02.04.004--Not Available
Malaise08.01.01.003--
Meningioma17.20.01.005; 16.30.01.005--Not Available
Menopausal symptoms21.02.02.002--Not Available
Menstruation irregular21.01.01.005; 05.05.01.008--
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages